Filing Flows › Comparisons › RAPP vs NAMS
Rapport Therapeutics vs NewAmsterdam Pharma Co N.V.: RAPP and NAMS compared
Rapport Therapeutics is the larger company: $20.0M of revenue in its latest quarter (Q1 2026) against $19.2M for NewAmsterdam Pharma Co N.V. (Q3 2026). Rapport Therapeutics is more profitable, with an operating margin of -121.1% against -230.6%.
Where the money goes: RAPP and NAMS
Rapport Therapeutics (RAPP) · Q1 2026
Rapport Therapeutics, Q1 2026: revenue $20.0M, operating margin -121.1%, net loss $19.9M, operating cash flow −$13.1M. The chart follows the revenue to costs, profit and cash.
NewAmsterdam Pharma Co N.V. (NAMS) · Q3 2026
NewAmsterdam Pharma Co N.V., Q3 2026: revenue $19.2M (55× year over year), operating margin -230.6%, net loss $17.4M, operating cash flow −$39.8M. The chart follows the revenue to costs, profit and cash.
| Rapport Therapeutics (RAPP) | NewAmsterdam Pharma Co N.V. (NAMS) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q3 2026 |
| Revenue | $20.0M | $19.2M |
| Revenue growth, Y/Y | — | 55× |
| Operating margin | -121.1% | -230.6% |
| Net earnings | −$19.9M | −$17.4M |
| Net margin | -99.3% | -90.7% |
| Operating cash flow | −$13.1M | −$39.8M |
Questions
Which is bigger, Rapport Therapeutics or NewAmsterdam Pharma Co N.V.?
Rapport Therapeutics is the larger company: $20.0M of revenue in its latest quarter (Q1 2026) against $19.2M for NewAmsterdam Pharma Co N.V. (Q3 2026).
Is Rapport Therapeutics or NewAmsterdam Pharma Co N.V. growing faster?
Rapport Therapeutics is more profitable, with an operating margin of -121.1% against -230.6%.
More: Rapport Therapeutics earnings · how Rapport Therapeutics makes money · NewAmsterdam Pharma Co N.V. earnings · how NewAmsterdam Pharma Co N.V. makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 7, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.